Literature DB >> 24510534

Optimization of individualized dynamic treatment regimes for recurrent diseases.

Xuelin Huang1, Jing Ning, Abdus S Wahed.   

Abstract

Patients with cancer or other recurrent diseases may undergo a long process of initial treatment, disease recurrences, and salvage treatments. It is important to optimize the multi-stage treatment sequence in this process to maximally prolong patients' survival. Comparing disease-free survival for each treatment stage over penalizes disease recurrences but under penalizes treatment-related mortalities. Moreover, treatment regimes used in practice are dynamic; that is, the choice of next treatment depends on a patient's responses to previous therapies. In this article, using accelerated failure time models, we develop a method to optimize such dynamic treatment regimes. This method utilizes all the longitudinal data collected during the multi-stage process of disease recurrences and treatments, and identifies the optimal dynamic treatment regime for each individual patient by maximizing his or her expected overall survival. We illustrate the application of this method using data from a study of acute myeloid leukemia, for which the optimal treatment strategies for different patient subgroups are identified.
Copyright © 2014 John Wiley & Sons, Ltd.

Entities:  

Keywords:  backward induction; causal inference; coarsening at random; optimal treatment sequence; recurrent events; survival analysis

Mesh:

Substances:

Year:  2014        PMID: 24510534      PMCID: PMC4043865          DOI: 10.1002/sim.6104

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  34 in total

1.  Nonparametric analysis of recurrent events and death.

Authors:  D Ghosh; D Y Lin
Journal:  Biometrics       Date:  2000-06       Impact factor: 2.571

2.  An experimental design for the development of adaptive treatment strategies.

Authors:  S A Murphy
Journal:  Stat Med       Date:  2005-05-30       Impact factor: 2.373

3.  Estimation of the causal effects on survival of two-stage nonrandomized treatment sequences for recurrent diseases.

Authors:  Xuelin Huang; Janice N Cormier; Peter W T Pisters
Journal:  Biometrics       Date:  2006-09       Impact factor: 2.571

4.  Comparing proportional hazards and accelerated failure time models: an application in influenza.

Authors:  Katie Patel; Richard Kay; Lucy Rowell
Journal:  Pharm Stat       Date:  2006 Jul-Sep       Impact factor: 1.894

5.  A joint frailty model for survival and gap times between recurrent events.

Authors:  Xuelin Huang; Lei Liu
Journal:  Biometrics       Date:  2007-06       Impact factor: 2.571

6.  Reinforcement learning design for cancer clinical trials.

Authors:  Yufan Zhao; Michael R Kosorok; Donglin Zeng
Journal:  Stat Med       Date:  2009-11-20       Impact factor: 2.373

7.  Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.

Authors:  E H Estey; P F Thall; S Pierce; J Cortes; M Beran; H Kantarjian; M J Keating; M Andreeff; E Freireich
Journal:  Blood       Date:  1999-04-15       Impact factor: 22.113

8.  Variable selection in the accelerated failure time model via the bridge method.

Authors:  Jian Huang; Shuangge Ma
Journal:  Lifetime Data Anal       Date:  2009-12-16       Impact factor: 1.588

9.  Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.

Authors:  Peter F Thall; Christopher Logothetis; Lance C Pagliaro; Sijin Wen; Melissa A Brown; Dallas Williams; Randall E Millikan
Journal:  J Natl Cancer Inst       Date:  2007-10-30       Impact factor: 13.506

10.  Evaluation of Viable Dynamic Treatment Regimes in a Sequentially Randomized Trial of Advanced Prostate Cancer.

Authors:  Lu Wang; Andrea Rotnitzky; Xihong Lin; Randall E Millikan; Peter F Thall
Journal:  J Am Stat Assoc       Date:  2012-06       Impact factor: 5.033

View more
  6 in total

1.  Doubly Robust Learning for Estimating Individualized Treatment with Censored Data.

Authors:  Y Q Zhao; D Zeng; E B Laber; R Song; M Yuan; M R Kosorok
Journal:  Biometrika       Date:  2015-03-01       Impact factor: 2.445

2.  Robustifying Trial-Derived Optimal Treatment Rules for A Target Population.

Authors:  Ying-Qi Zhao; Donglin Zeng; Catherine M Tangen; Michael L LeBlanc
Journal:  Electron J Stat       Date:  2019-04-30       Impact factor: 1.125

3.  Identifying cost-effective dynamic policies to control epidemics.

Authors:  Reza Yaesoubi; Ted Cohen
Journal:  Stat Med       Date:  2016-07-24       Impact factor: 2.373

4.  A cure-rate model for Q-learning: Estimating an adaptive immunosuppressant treatment strategy for allogeneic hematopoietic cell transplant patients.

Authors:  Erica E M Moodie; David A Stephens; Shomoita Alam; Mei-Jie Zhang; Brent Logan; Mukta Arora; Stephen Spellman; Elizabeth F Krakow
Journal:  Biom J       Date:  2018-05-16       Impact factor: 2.207

5.  Interactive Q-learning for Quantiles.

Authors:  Kristin A Linn; Eric B Laber; Leonard A Stefanski
Journal:  J Am Stat Assoc       Date:  2017-03-31       Impact factor: 5.033

6.  Differences in predictions of ODE models of tumor growth: a cautionary example.

Authors:  Hope Murphy; Hana Jaafari; Hana M Dobrovolny
Journal:  BMC Cancer       Date:  2016-02-26       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.